|
Roche, FDA announce new drug-interaction warnings for mibefradil. |
1998 |
Am J Health Syst Pharm |
pmid:9492249
|
Ku YM et al. |
Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. |
1995 |
Am J Health Syst Pharm |
pmid:8528874
|
Greanya ED et al. |
Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. |
2012 |
Am J Health Syst Pharm |
pmid:22215359
|
Curtin BF et al. |
Unusually late-onset mycophenolate mofetil-related colitis. |
2014 |
Am J Health Syst Pharm |
pmid:25320135
|
Bonhomme-Faivre L et al. |
Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. |
2009 |
Am J Health Syst Pharm |
pmid:19729569
|
Lee JH et al. |
Stability of tacrolimus solutions in polyolefin containers. |
2016 |
Am J Health Syst Pharm |
pmid:26796907
|
|
Tacrolimus. |
2001 |
Am J Health Syst Pharm |
pmid:11794952
|
Lee B et al. |
Appropriate timing of tacrolimus concentration measurements in the emergency department. |
2016 |
Am J Health Syst Pharm |
pmid:27543574
|
Pennington CA and Park JM |
Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. |
2015 |
Am J Health Syst Pharm |
pmid:25631834
|
Tsapepas DS et al. |
Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient. |
2011 |
Am J Health Syst Pharm |
pmid:21200061
|
Grouzmann E et al. |
Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration. |
2008 |
Am J Health Syst Pharm |
pmid:18216007
|
Kasper RC et al. |
Anetoderma arising in cutaneous B-cell lymphoproliferative disease. |
2001 |
Am J Dermatopathol |
pmid:11285407
|
Breuer K et al. |
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. |
2005 |
Am J Clin Dermatol |
pmid:15799678
|
Cheer SM and Plosker GL |
Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. |
2001 |
Am J Clin Dermatol |
pmid:11770393
|
Ozden MG et al. |
Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study. |
2010 |
Am J Clin Dermatol |
pmid:20000875
|
Patel TS et al. |
Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. |
2007 |
Am J Clin Dermatol |
pmid:17645374
|
Mertens JS et al. |
Morphea and Eosinophilic Fasciitis: An Update. |
2017 |
Am J Clin Dermatol |
pmid:28303481
|
Wellington K and Noble S |
Pimecrolimus: a review of its use in atopic dermatitis. |
2004 |
Am J Clin Dermatol |
pmid:15663345
|
Cook BA and Warshaw EM |
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. |
2009 |
Am J Clin Dermatol |
pmid:19222250
|
Ingram JR et al. |
Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. |
2009 |
Am J Clin Dermatol |
pmid:19489656
|